Comments
The Indian Patents Office on Thursday rejected an application of global pharma major Johnson and Johnson seeking an extension of its patent on anti-Tuberculosis (TB) drug Bedaquiline beyond July 2023, when it is set to expire. Why is this significant? Will it help TB patients in India?
The Hindu businessline’s Senior Deputy Editor G Naga Sridhar explains in this episode of News Explained. Tune in to know more.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.